Antitumor activity of dostarlimab by PD-L1 and tumor mutation burden (TMB) in patients (pts) with mismatch repair deficient and proficient (dMMR and MMRp) tumors in the GARNET trial

Category Primary study
JournalCancer Research
Year 2022
This article has no abstract
Epistemonikos ID: 4e6ad04a914bc5bd0b1666e12c45e37aa67dcb89
First added on: Feb 14, 2025